Odontostomatological University Centre, Department of Medicine and Surgery, University of Perugia, 06132 Perugia, Italy.
Section of General Pathology, Department of Medicine and Surgery, University of Perugia, 06132 Perugia, Italy.
Pharmacol Res. 2022 Jul;181:106267. doi: 10.1016/j.phrs.2022.106267. Epub 2022 May 25.
This systematic review examine the biological effects of CBD, a major component of therapeutic Cannabis, on human pathological and cancer cell populations of integumentary, gastro-intestinal, genital and breast, respiratory, nervous, haematopoietic and skeletal districts in terms of cell viability, proliferation, migration, apoptosis, inflammation, metastasis, and CBD receptor expression. The included studies were in English, on human cell lines and primary culture from non-healthy donors with CBD exposure as variable and no CBD exposure as control. Quality assessment was based on ToxRtool with a reliability score ranging from 15 to 18. Following the PRISMA statement 4 independent reviewers performed an electronic search using MEDLINE via PubMed, Scopus and Web of Science. From 3974 articles, 83 studies have been selected. Data showed conflicting results due to different concentration exposure, administrations and time points. CBD inhibited cell viability and proliferation in most cellular districts except the integumentary apparatus. Also a significant inhibition of migration was observed in all cell types, while an increase in apoptosis at both high and low doses (greater and less than 10 μM respectively). Considering inflammation, CBD caused an anti-inflammatory effect on nervous cells at low doses and on gastro-intestinal cells at high doses, while metastatic power was reduced even at low doses, but in a skeletal cell line there was an increased angiogenesis. CB1 receptor has been related to viability effects, CB2 to apoptosis and TRPV1 to inflammation and invasiveness. A detailed insight into these aspects would allow therapeutic use of this substance without possible side effects.
这篇系统综述探讨了 CBD（医用大麻的主要成分）对皮肤、胃肠道、生殖和乳腺、呼吸、神经、造血和骨骼等部位病理性和癌细胞系的生物学效应，包括细胞活力、增殖、迁移、凋亡、炎症、转移和 CBD 受体表达等方面。纳入的研究为英文，在非健康供体来源的人类细胞系和原代培养物中进行，以 CBD 暴露为变量，无 CBD 暴露为对照。质量评估基于 ToxRtool，可靠性评分为 15-18 分。按照 PRISMA 声明，4 位独立评审员使用 MEDLINE 通过 PubMed、Scopus 和 Web of Science 进行了电子检索。从 3974 篇文章中，选择了 83 项研究。由于不同的浓度暴露、管理和时间点，数据显示出相互矛盾的结果。CBD 抑制了大多数细胞区室的细胞活力和增殖，除了皮肤外。此外，所有细胞类型的迁移都显著受到抑制，而在高剂量和低剂量下（分别大于和小于 10 μM）都观察到凋亡增加。考虑到炎症，CBD 在低剂量下对神经细胞、高剂量下对胃肠道细胞产生抗炎作用，而即使在低剂量下，转移能力也会降低，但在骨骼细胞系中，血管生成增加。CB1 受体与活力效应有关，CB2 受体与凋亡有关，TRPV1 受体与炎症和侵袭性有关。深入了解这些方面将允许在没有可能的副作用的情况下对这种物质进行治疗应用。
